Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Selecta Biosciences Receives $3 Million from NIH/NIDA to Develop Nicotine Vaccine for Smoking Cessation

Abstract:
Targeted Synthetic Vaccine Particles (tSVP) Offer Potential for Increased Anti-Nicotine Efficacy to Increase Success of Smoking Cessation

Selecta Biosciences Receives $3 Million from NIH/NIDA to Develop Nicotine Vaccine for Smoking Cessation

Watertown, MA | Posted on August 16th, 2010

Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines and immunotherapies, today announced that it has been awarded a grant for $3 million from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health (NIH). The grant is aimed at advancing the development of an enhanced therapeutic nicotine vaccine for the treatment of smoking cessation and relapse prevention.

The $3 million grant will support the funding of a clinical drug candidate from Selecta's pipeline, and assist with advancing a nicotine vaccine from preclinical through early clinical evaluation. The award is one of a select number of grants provided nationwide by NIH under the unique BRDG-SPAN program (Biomedical Research and Development and Growth To Spur the Acceleration of New Technologies Pilot Program) which is designed to bridge the gap between R&D and commercialization for promising new medical technologies.

"We are delighted that NIDA has recognized the uniqueness and potential advantages of Selecta's synthetic therapeutic vaccines and has elected to support Selecta's tSVP nicotine vaccine, in a very competitive process, to address the enormous unmet medical need of smoking cessation," said Werner Cautreels, Ph.D., Chief Executive Officer of Selecta Biosciences. "We view a nicotine vaccine as one of our promising programs that are poised to advance into human clinical trials based on our progress with Selecta's technology platform"

Selecta's tSVP technology offers in this case a new approach to a nicotine vaccine designed to boost immune responses, or more specifically nicotine antibody titers, beyond previous technologies. Selecta's tSVP immunomodulatory nanoparticles aim to induce highly predictable immune responses, for durable effect in smoking cessation. Although previous research has shown the therapeutic potential for vaccinating against nicotine by inducing nicotine-specific antibodies, published studies with differently designed vaccines show that only a small fraction of study patients achieved anti-nicotine titers sufficient to increase smoking cessation above placebo.

####

About Selecta Biosciences
Selecta Biosciences, Inc. is a biopharmaceutical company developing first-in-class synthetic nanoparticle vaccines and immunotherapies, with the first applications focused on nanoparticle vaccines using its proprietary targeted Synthetic Vaccine Particle (tSVP™) technology. The tSVP platform enables full-integration of the key vaccine components, antigens and adjuvants, for highly-effective targeting to immune cells to produce an optimal immune response. The tSVP vaccines mimic the structure of natural pathogens with regards to size, shape and the sequence of immunological information that it delivers specifically to immune cells, thus harnessing the body's defense system to produce a robust immune response. The unique attributes of full-integration, targeting and natural structure conferred by the tSVP platform create synthetic nanoparticle vaccines that are engineered for unprecedented safety and efficacy. This novel approach enables expanded opportunities for tSVP vaccines, and the company is pursuing opportunities across a range of high unmet medical need applications, including infectious, metabolic, CNS and inflammatory diseases.

Selecta was founded in 2008 by three academic pioneers in the fields of nanotechnology and immunology: Professor Robert Langer (MIT), and Professors Omid Farokhzad and Ulrich von Andrian (Harvard Medical School). Selecta is backed by leading venture investors including, Polaris Venture Partners, Flagship Ventures, NanoDimension, OrbiMed Advisors and Leukon Investments. For more information please visit the company website at www.selectabio.com.

About Smoking Cessation
Through the use of tobacco, nicotine is one of the most heavily used addictive drugs and smoking is the leading preventable cause of disease, disability, and death in the United States. According to the CDC there are approximately 438,000 premature deaths in the U.S. per year due to smoking and approximately 38,000 lung cancer and heart disease deaths annually were attributable to exposure to secondhand smoke. Additionally, smoking costs the U.S. $97 billion dollars a year in direct healthcare costs and an additional $92 billion a year in productivity losses.

For more information, please click here

Contacts:
Gina Nugent
The Yates Network
Tel: 617-460-3579

Copyright © Selecta Biosciences

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Researchers develop artificial building blocks of life March 8th, 2024

How surface roughness influences the adhesion of soft materials: Research team discovers universal mechanism that leads to adhesion hysteresis in soft materials March 8th, 2024

Two-dimensional bimetallic selenium-containing metal-organic frameworks and their calcinated derivatives as electrocatalysts for overall water splitting March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

Nanomedicine

High-tech 'paint' could spare patients repeated surgeries March 8th, 2024

Researchers develop artificial building blocks of life March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Announcements

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

Personal Care/Cosmetics

DGIST and New Life Group launched a research project on "Functional beauty and health products using the latest nanotechnology" May 12th, 2023

A Comprehensive Guide: The Future of Nanotechnology September 13th, 2018

Graphene finds new application as anti-static hair dye: New formula works as well as commercial permanent dyes without chemically altering hairs March 22nd, 2018

Programmable materials find strength in molecular repetition May 23rd, 2016

Grants/Sponsored Research/Awards/Scholarships/Gifts/Contests/Honors/Records

Discovery of new Li ion conductor unlocks new direction for sustainable batteries: University of Liverpool researchers have discovered a new solid material that rapidly conducts lithium ions February 16th, 2024

$900,000 awarded to optimize graphene energy harvesting devices: The WoodNext Foundation's commitment to U of A physicist Paul Thibado will be used to develop sensor systems compatible with six different power sources January 12th, 2024

Catalytic combo converts CO2 to solid carbon nanofibers: Tandem electrocatalytic-thermocatalytic conversion could help offset emissions of potent greenhouse gas by locking carbon away in a useful material January 12th, 2024

'Sudden death' of quantum fluctuations defies current theories of superconductivity: Study challenges the conventional wisdom of superconducting quantum transitions January 12th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project